Milestone: First patient treated in multicenter clinical trial

14 September 2016

AQLANE Medical™ is pleased to announce the first patient has been enrolled and treated in their multicenter clinical trial entitled “The use of a Polycaprolactone Based Bulking Agent for the Treatment of Female Stress Urinary Incontinence (SUI), a Pivotal Trial”.

aqlane medical, utrecht, netherlands, bioresorbale, medical solutions, medical device, voiding dysfunction, EN ISO 13485:2016

This 2-year clinical trial, with a planned extension out to 5-years, will evaluate the safety and efficacy of the novel urethral bulking agent Urolon™ in female patients with mild to moderate SUI.